TABLE 1.
Clinical Demographics, Diagnostic Clinical Features, and Therapeutic Courses for Each Study Participant
| Case ID | Eye | Sex | Age at DX (mo) | Laterality | IIRC (TNM) | Family History of RB? | Vitreous Seeding at DX | Initial Treatment | Seeding Recurrence? | Retinal Recurrence? | Total Sample Number | Time to Enucleation (mo) | Follow-up From DX (mo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 33 | OS | M | 22 | U | D (CT2B) | Negative | Sphere | IAC | Yes | No | 5 | 5 | 47 |
| 44 | OD | M | 4 | B | B (CT1B) | Negative | None | IVC | No | No | 2 | n/a | 55 |
| — | OS | M | 4 | B | D (CT2B) | Negative | Dust | IVC | Yes | Yes | 11 | n/a | 55 |
| 45 | OD | F | 8 | U | D (CT2B) | Negative | None | IVC | No | No | 1 | n/a | 56 |
| 46 | OS | M | 5 | U | C (CT2A) | Negative | None | IVC | No | No | 2 | n/a | 37 |
| 47 | OD | F | 15 | U | D (CT2B) | Negative | Sphere | IVC | Yes | No | 4 | n/a | 46 |
| 48 | OD | M | 18 | U | D (CT2B) | Negative | Cloud | IAC | No | Yes | 1 | 1 | 47 |
| 51 | OD | M | 30 | U | D (CT2B) | Negative | Dust | IAC | No | No | 3 | n/a | 41 |
| 55 | OS | M | 24 | U | D (CT2B) | Negative | Sphere | IAC | Yes | No | 3 | 5 | 38 |
| 64 | OD | F | 15 | B | D (CT2B) | Negative | Sphere | IVC | No | No | 1 | n/a | 36 |
| 65 | OS | M | 24 | U | D (CT2B) | Negative | Cloud, sphere | PE | n/a | n/a | 2 | 0 | 34 |
| 66 | OS | F | 24 | B | D (CT2B) | Negative | Cloud | IAC | Yes | No | 5 | 9 | 35 |
| 67 | OS | M | 24 | U | D (CT2B) | Negative | Dust | IAC | No | Yes | 2 | 2 | 29 |
| 70 | OD | M | 2 | B | A (CT1A) | Positive | None | Laser | No | No | 1 | n/a | 33 |
| — | OS | M | 2 | B | A (CT1A) | Positive | None | Laser | No | No | 1 | n/a | 33 |
| 72 | OD | F | 27 | B | A (CT1A) | Positive | None | IVC | No | No | 1 | n/a | 24 |
| — | OS | F | 27 | B | D (CT2B) | Positive | Cloud | IVC | No | Yes | 1 | 7 | 24 |
| 73 | OS | M | 35 | U | D (CT2B) | Negative | Cloud | IVC | Yes | No | 16 | n/a | 22 |
| 74 | OD | F | 4 | B | B (CT1B) | Negative | None | IVC | No | Yes | 4 | n/a | 21 |
| — | OS | F | 4 | B | C (CT2B) | Negative | Subretinal | IVC | No | No | 3 | n/a | 21 |
| 76 | OS | M | 46 | U | D (CT2B) | Negative | Subretinal | IVC | Yes | No | 7 | n/a | 21 |
| 78 | OS | M | 4 | U | C (CT2B) | Negative | Subretinal | IVC | No | No | 3 | n/a | 21 |
| 83 | OS | F | 8 | U | D (CT2B) | Negative | Sphere | Bridge IAC | No | No | 1 | n/a | 18 |
| 84 | OD | M | 6 | U | D (CT2B) | Negative | Dust | IVC | Yes | No | 4 | n/a | 16 |
| 88 | OD | M | 5 | B | E (CT3C) | Negative | Dust | IVC | Yes | No | 2 | n/a | 12 |
| — | OS | M | 5 | B | C (CT2B) | Negative | Sphere | IVC | Yes | No | 3 | n/a | 12 |
B = bilateral, DX = diagnosis, IAC = intra-arterial chemotherapy, IIRC = International Intraocular Retinoblastoma Classification, IVC = systemic intravenous chemotherapy, n/a = not applicable, PE = primary enucleation, RB = retinoblastoma, TNM = tumor, nodes, metastases, U = unilateral.